Available Exclusively From



Expanded Bacterial Vaginosis (BV) Testing

MDL has expanded the Bacterial Vaginosis (BV) Panel with Lactobacillus Profiling by qPCR test to allow for a more sensitive and specific determination of BV status, especially when considering the variation among patient vaginal microbial composition and the complex interactions that occur leading to dysbiosis. As BV can be a polymicrobial infectious process involving species that differ among patients with overlapping symptoms with other vaginal disorders, it is critical for an accurate diagnosis to include a comprehensive selection of "pathogenic" bacteria when testing for BV. It also is important to include the detection of Lactobacilli that support vaginal health, whether naturally occurring or introduced by probiotic use, as well as any bacteria that more accurately indicate the transition between a healthy, stable vaginal flora and BV flora.

Test 759 Bacterial Vaginosis (BV) Panel with Lactobacillus Profiling by qPCR Includes

- Fannyhessea vaginae (Atopobium vaginae)
- Bacterial Vaginosis Associated Bacteria 1 (BVAB1)
- Bacterial Vaginosis Associated Bacteria 2 (BVAB2)
- Bacterial Vaginosis Associated Bacteria 3 (BVAB3)
- Bacteroides fragilis
- Bifidobacterium breve
- Gardnerella vaginalis
- Megasphaera type 1
- Megasphaera type 2
- Mobiluncus curtisii

- Mobiluncus mulieris
- Prevotella bivia
- Sneathia sanguinegens
- Streptococcus anginosus
- Lactobacillus crispatus
- Lactobacillus gasseri
- Lactobacillus jensenii
- Lactobacillus iners
- Lactobacillus acidophilus

Advantages:

- Includes 14 BV-associated organisms with Lactobacillus Profiling
- Improved sensitivity and specificity to better correlate symptom presentations with BV
- Improved resolution and definition of transitional BV.
- MDL's BV Panel accounts for more than 99% of BV infections.
- F. vaginae (A. vaginae) is frequently co-existent with Gardnerella, and both can be resistant to metronidazóle.
- F. vaginae (A. vaginae), Megasphaera and BVAB2 cannot be detected under the microscope.
- Accurate vaginal microbiome assessment with Lactobacillus profiling at no additional charge.
- Lactobacillus profiling indicates the concentration of pathogenic bacteria relative to lactobacillus, enabling tailored treatment decisions based on the pathogen and infection severity.
- Includes Lactobacillus acidophilus, a common probiotic bacteria used to treat BV and establish a healthy vaginal microenvironment.

References:

ThinPrep

A MEMBER OF GENESIS BIOTECHNOLOGY GROUP

- Diagnosis of Vaginitis 2022, October 31. "Diagnosis of Vaginitis".
- https://www.aetna.com/cpb/medical/data/600_699/0643.html Workowski KA, Bachmann LH, Chan PA, et al. 2021, July 23. "Sexually Transmitted Infections Treatment Guidelines, 2021". https://www.cdc.gov/mmwr/volumes/70/rr/rr7004a1.htm









Medical Diagnostic Laboratories L.L.C.

2439 Kuser Road Toll Free: 877-269-0090 Hamilton, NJ 08690 609-570-1050 Fax:

www.mdlab.com





MDL#

10100864

FINAL

DOE, JANE

2439 KUSER RD TRENTON, NJ 08690

DOB: 01/01/1985 (Age 39)

Gender: Female

Ethnicity: Hispanic or Latino

78452PP Patient ID:

CLIENT

NPI: 2121212121

JOHN DOE MD JOHN DOE, MD HOUSTON, USA

TEST

HOUSTON, GU 23890

Tel: (244) 144-4233 Fax: 452-333-4444

Bacterial Vaginosis Panel (with Lactobacillus Profiling) by QPCR 759

Indicative of Abnormal microflora.

Suggestive of Bacterial Vaginosis.



Bacteria Detected

142 Atopobium vaginae

179 Lactobacillus iners

BV

Indicator

Transitional

Abundance

90.00% 10.00%

Q REPORT HISTORY

See Bacterial Vaginosis/ Aerobic Vaginitis Trend Report for prior Dates of Service

10/30/2023

02/21/2024

04/03/2024

750

764

Pathogens Not Detected

Bifidobacterium breve *

125 Bacteroides fragilis *

BVAB1 *

765 132

165

BVAB3 *

Gardnerella vaginalis *

752 Prevotella bivia

Megasphaera species (Type1,Type2

749 748

754

Sneathia sanguinegens * Streptococcus anginosus *

Mobiluncus mulieris *

164 BVAB2 *

Mobiluncus curtisii **753**

*This test was developed and its performance characteristics determined by the laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

A positive result is provided for bacteria, virus, parasites, and/or fungal species when PCR amplification (real-time PCR), sequence information (Pyrosequencing), and/or sequencing analysis occurs above cut-off levels established by the laboratory. Pertinent reference intervals for the tests reported above are available from the laboratory upon request.

Medical Director, Jing-Jing Yang, M.D.

MDL#: 10100864

04/03/2024